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DESPITE improvements in operative techniques. or· 
.... preservation. and the inuodUdion of OKn, the 
incidence of retranspianWion (RET,,) under cyclosporine 
(CyA).based therapy hu changed litde since our initial 
repon. I - J Approximately 15% to 20% of all CyA·treated 
recipients require RET". with a I·year mortality rate of 
5095. 
The purpose of this study was to evaluate the impact of 
FK 506 on the incidence of RETx and on the cause of graft 
loss. 
CASE MATERIALS 
CyAGroup 
Between October 25. 1987 and September 5. 1989. 631 adult 
patients 118 years or older) received their first orthotopic: liver 
transplantation IOLTx) underCyA-steroid therapy at the Univer· 
sity Health Center of Pillsbul'lh. Within the first 6 months 
followinlthe OLT. 97 adults patients had required 118 retrans· 
plantations (RETx) (97 second. 19 third. and 2 fourth). Median 
follow-up in this group was 27 months. 
Four patients initially treated with CyA had unsuccessful at· 
tempts at rescue with FK 506 before RETx. Followinl RETx. 18 
patients were switched to FK 506. For the purpose of analysis. 
these patients were included in the CyA RrOuP. 
FK 506 Group 
Between AUIUSl 19. 1989 and September 30. 1990. 409 adults 
received primary liver gratts under FK 506 and low-dose steroid 
therapy. Thiny-tive pallents required 39 RETxs 135 second. " 
thirdl within the first 6 months followlftlthe pnrnary transplanta· 
lion. Median follow-up 1ft this IrouP was 13 months. 
Organ PreservatIOn 
All of the liver allOlflfis in this study were preserved with the 
University of WisconSin solution. 
Patient SUrviVal. Follow-Up. and Statistics 
The indicallon for RETx from clinical and pathologiC eVidence 
was claSSified as: I-Iechnlc:a.i. 2-reJection. }..;Jnmary nonfunc-
lion. 4-lnfection. and 5-fmscellaneous. A diqnosls of primary 
nonfunctlon was made If a graft never demonstrated evidence of 
Initial function follOWing transplantauon. Clinical findings and 
exanunallons stronl!ly associated with pnmary nontuncuon an· 
.:Iuded sta(le 4 coma. slulIIsh or no bile !low. ProlfCsslve Jaun· 
dice. uncorrec:table coaguJopathy. metabolic aCidosis. renal fail· 
ure. and cardiodynanuc shock. The pathology of such lrafts 
usualiy showed masSIve or submasslve Ischemic necrosIs. or 
severe choieslaSlS without eVidence of rejection. A technical 
classification was asSlped to all Rrafts faililll from vascular 
thromboses. complications of biliary reconstruction. or other 
erran in operative technique. The miscellaneous c:atelory in. 
cluded anfts lost from causes such as ruptured spicaic aneurysm 
and rcc:umnc:c of ori_ disease_ 
'The patient survival was calc:ulated from the dale of second 
tr'lllSJlIant. The minimum observation periods were 14 months in 
the eyA IfOUJI and 9 months in the FK 506pouJl. The survival 
rates were calculated by the Kaplan-Meier method. and statislic:a.l 
a_ysis were performed by Breslow method usiRl BMDP statls. 
tical software. Other statistical methods used were the Mann-
Whitney U rank·sum test. Kruskal·Wallis test. and Yates cor. 
rected chi·square analysis. P < .05 was considered statistically 
sipific:anl. 
RESULTS 
The Incidence of and Survivals After RetranspiantatiOn 
The incidence of RETx within 6 months of primary trans-
plantation was 15.4% (97 of 631) in the CyA group. and 
8.6% (35 of 4(9) in the FK 506 group (Table I). The lower 
incidence in the FK 506 group was significant (P < .005). 
One and 6 months patient survival rates after RETx 
were 69.1% and 54.6%. respectively, in the CyA group. 
and 85.7% and 62.9% in the FK 506 group (Fig I). The 
differences in the two groups were not significantly dif· 
ferent (P = .49 by Breslow method). 
Table 1. The incidence of Uvw RIIlrllnllJll8llt8tlon In the 
Am II Month. 
CyA Group FK 508Grouo PValue 
No. of Patients 631 40& 
Age(YI 18.1-73.9 1UK1~TK9 
Second Ira....,. 97 (15.4%) 35(8.6%) <005 
third transplant 19 4 
Fourth transplant 2 0 
Total RETx in tile flISt II months 118 (18.7"'0) 39(9.5"'.) ... 005 
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Fig 1. Patient sUMvals In the CyA and FK 506 groups following 
retransplantatlon. The sUMval was calcUlated from the date of 
second liver transplant. No statistical significance was observed In 
these two groups (P = ,49). 
The Cause of Graft Failure In RETx 
The causes of graft loss were grouped in five categories 
(Fig 2). Primary nonfunction t PNFI was the most common 
cause for RETx in both groups. Nonetheless. the inci-
dence of PNF was significantly lower in the FK 506 group 
when compared to the Cy A group 14.1% vs 7.4%. P < .05). 
Cold ischemic times were 14.5 :: 6.2 hours in the FK 506 
group. and 15.7 :: 7.1 hours in the CyA group (P = .65). 
Percentages of graftS whose cold ischemic times were 
more than 18 hours were not significantly different 131.3% 
vs 33.3%). 
Rejecllon was the third leading cause of graft failure with 
an incidence of 2.9% (18 of 631) in the eyA group. Ten of 
these primary grafts failed from acute cellular rejection 
within 8 to 31 days (median II days I. One graft failed from 
antibody-mediated rejection with partial portal vein throm-
bOSIS. Another graft failed from antibody-mediated reJec-
tion due to ABO incompatibility. Six grafts were lost to 
chroniC rejection with prominent bile duct damage or bile 
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Ag 2. The cause of graft failure In liver RETx. The inCIdet ICe of 
re,eclJOn and pnmary nontundlon deausecl significantly In ttle FK 
506 group (p < ,025 and P < ,05. reSC*IMI!V) when compared to 
the CyA group. PNF. pnmary nonfunc:llon; TEC. led1nlCal pro()-
lems; otner. miscellaneOUS causes. 
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duct loss within 49 to 165 days after transplantation 
(median 125 days). Although three of those six patients 
were switched to FK 506 for attempt to rescue at 22. 88. 
and 128 days after the primary transplantation. they re-
quired RETx 9, 26. and 60 days later and two patients 
survived. 
The incidence of rejection was significantly decreased in 
the FK 506 group 10.5%. 2 of 4(9) when compared with the 
eyA group (2.9%. 18 of 631. P < .025). In the FK 506 
group. two grafts failed from antibody-mediated rejection. 
The Iymphocytotoxic crossmatch tests of both patients 
were strongly positive. and both of these grafts were lost at 
3 and 38 days. respectively. No acute cellular rejection 
was observed as the cause of graft loss. Furthermore. no 
chronic rejection was observed in the FK 506 group within 
the first 6 months. 
There was no significant difference in the incidence of 
technical problems or infections in these two groups of 
patients. 
DISCUSSION 
Successful RETx of the liver was first accomplished as 
early as 1967. 1 However. the morbidity and mortality from 
such efforts were so overwhelming that RETx was a highly 
questionable undertaking until the advent of CyA. 
During our first 5 years ofCyA use (1980101984).18.6% 
of patients required RETx.l This incidence has changed 
little in the ensuing years. In the present study of Cy A 
cases t1987 to 1989), in which the basic immunosuppres-
sive therapy was with eyA and steroids supplemented by 
OKT3 and/or azathioprine. the rate of RETx was 15.4%. 
Interestingly. rejection as the cause for graft loss declined 
from 8.7% to 2.9%. 
The introduction of the new Immunosuppressant FK 506 
decreased the need for RETx from 15.4% to 8.6% (P < 
,005). One reason for this significantly lower Incidence of 
RETx was a further decrease in grafts lost to rejection to 
0.5%. Only two grafts were lost to rejection. and in both 
cases. the Iymphocytotoxlc crossmatch test was strongly 
positive. These patients reqUired RETx within 3 and 38 
days. even though high-dose sterOids and OKT3 therapy 
were used. RETx rates in all positive crossmatch patients 
were 23.6% in the eyA group. and 24.2% in the FK 506 
group. respectively. The need for RETx appeared to be 
higher in positive crossmatch patients. regardless of the 
immunosuppression.4.3 
The incidence of primary nonfunction. although reduced 
in both groups from our initial reports. was reduced even 
more in the FK 506 group (4.2% vs 7.4% in eyA group. 
P < .05). The reason for this is not clear. There was no 
significant difference in cold ischemiC times between the 
eyA and FK 506 groups. and the difference might be 
related to the hepatotrophic activity of FK 5066 and/or 
more complete restortlon of hepatic A TP after reperi"usion 
in FK 50Mreated patients. 1 
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